Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations-Reference-Cited by-同舟云学术

Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations

Published:2019-12 Issue:8 Volume:19 Page:1067-1073
ISSN:1424-3903
Container-title:Pancreatology
language:en
Short-container-title:Pancreatology

Author:

Panzuto Francesco^ORCID,Pusceddu Sara,Faggiano Antongiulio,Rinzivillo Maria,Brighi Nicole,Prinzi Natalie,Riccardi Ferdinando,Iannicelli Elsa,Maggio Ilaria,Femia Daniela,Tafuto Salvatore,Manuzzi Lisa,Di Sarno Antonella,Annibale Bruno,de Braud Filippo,Campana Davide

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Endocrinology, Diabetes and Metabolism

Reference26 articles.

1. A prognostic scoring system for the prediction of metastatic recurrence following curative resection of pancreatic neuroendocrine tumors;Sho;J Gastrointest Surg,2018

2. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors;Pusceddu;Endocr Relat Cancer,2018

3. Stage IV gastro-entero-pancreatic neuroendocrine neoplasms: a risk score to predict clinical outcome;Panzuto;Oncologist,2017

4. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system;Rindi;Virchows Arch,2006

5. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system;Rindi;Virchows Arch,2007

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Considerations on the preliminary results of the NETTER-2 trial: is the glass half full or half empty?;Clinical and Translational Imaging;2024-05-07

2. Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?;Frontiers in Medicine;2024-01-15

3. Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs;Cancer Imaging;2023-04-25

4. Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors;Current Oncology;2023-01-18

5. Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib;Chinese Journal of Cancer Research;2023